The role of Forkhead-box Class O (FoxO) transcription factors in cancer: A target for the management of cancer

Toxicology and Applied Pharmacology

Volumn 224, Issue 3, 2007, Pages 360-368

  Reagan Shaw, Shannon ^a   Ahmad, Nihal ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apoptosis; Cancer; Cell cycle; Forkhead; FoxO; Transcription factor; Tumor suppression

Indexed keywords

TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO 2; TRANSCRIPTION FACTOR FOXO 4; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CHEMOPROPHYLAXIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; NONHUMAN; REVIEW;

ANIMALS; APOPTOSIS; EPITHELIAL CELLS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 35348852474     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.12.003     Document Type: Review

References (68)

1. Accili D., and Arden K.C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 (2004) 421-426
2. Alvarez B., Martinez A., Burgering B.M., and Carrera A.C. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413 (2001) 744-747
3. Arimoto-Ishida E., Ohmichi M., Mabuchi S., Takahashi T., Ohshima C., Hayakawa J., Kimura A., Takahashi K., Nishio Y., Sakata M., Kurachi H., Tasaka K., and Murata Y. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology 145 (2004) 2014-2022
4. Baxter F.O., Came P.J., Abell K., Kedjouar B., Huth M., Rajewsky K., Pasparakis M., and Watson C.J. IKK{beta}/2 induces TWEAK and apoptosis in mammary epithelial cells. Development 133 (2006) 3485-3494
5. Bravou V., Klironomos G., Papadaki E., Taraviras S., and Varakis J. ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J. Pathol. 208 (2006) 91-99
6. Brownawell A.M., Kops G.J., Macara I.G., and Burgering B.M. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol. Cell. Biol. 21 (2001) 3534-3546
7. Brunet A., Park J., Tran H., Hu L.S., Hemmings B.A., and Greenberg M.E. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21 (2001) 952-965
8. Brunet A., Kanai F., Stehn J., Xu J., Sarbassova D., Frangioni J.V., Dalal S.N., DeCaprio J.A., Greenberg M.E., and Yaffe M.B. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J. Cell Biol. 156 (2002) 817-828
9. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., and Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303 (2004) 2011-2015
10. Burgering B.M., and Kops G.J. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27 (2002) 352-360
11. Ciechomska I., Pyrzynska B., Kazmierczak P., and Kaminska B. Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells. Oncogene 22 (2003) 7617-7627
12. Davis R.J., D'Cruz C.M., Lovell M.A., Biegel J.A., and Barr F.G. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 54 (1994) 2869-2872
13. del Peso L., Gonzalez V.M., Hernandez R., Barr F.G., and Nunez G. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18 (1999) 7328-7333
14. Epstein J.A., Song B., Lakkis M., and Wang C. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol. Cell. Biol. 18 (1998) 4118-4130
15. Essers M.A., de Vries-Smits L.M., Barker N., Polderman P.E., Burgering B.M., and Korswagen H.C. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308 (2005) 1181-1184
16. Ghatak S., Misra S., and Toole B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem. 277 (2002) 38013-38020
17. Greer E.L., and Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24 (2005) 7410-7425
18. Guo S., and Sonenshein G.E. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol. Cell. Biol. 24 (2004) 8681-8690
19. Hosaka T., Biggs III W.H., Tieu D., Boyer A.D., Varki N.M., Cavenee W.K., and Arden K.C. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2975-2980
20. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., and Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003) 191-196
21. Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y., Zou Y., Bao S., Hanada N., Saso H., Kobayashi R., and Hung M.C. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117 (2004) 225-237
22. Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M., and Tindall D.J. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1649-1654
23. Hussain A.R., Al-Rasheed M., Manogaran P.S., Al-Hussein K.A., Platanias L.C., Al K.K., and Uddin S. Curcumin induces apoptosis via inhibition of PI3-kinase/AKT pathway in acute T cell leukemias. Apoptosis 11 (2006) 245-254
24. Jackson J.G., Kreisberg J.I., Koterba A.P., Yee D., and Brattain M.G. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene 19 (2000) 4574-4581
25. Jacobs F.M., van der Heide L.P., Wijchers P.J., Burbach J.P., Hoekman M.F., and Smidt M.P. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J. Biol. Chem. 278 (2003) 35959-35967
26. Jonsson H., Allen P., and Peng S.L. Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nat. Med. 11 (2005) 666-671
27. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev., Cancer 2 (2002) 301-310
28. Katoh M., and Katoh M. Human FOX gene family (Review). Int. J. Oncol. 25 (2004) 1495-1500
29. Kau T.R., Schroeder F., Ramaswamy S., Wojciechowski C.L., Zhao J.J., Roberts T.M., Clardy J., Sellers W.R., and Silver P.A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4 (2003) 463-476
30. Kawamori D., Kaneto H., Nakatani Y., Matsuoka T.A., Matsuhisa M., Hori M., and Yamasaki Y. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J. Biol. Chem. 281 (2006) 1091-1098
31. Keller C., and Capecchi M.R. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res. 65 (2005) 7530-7532
32. Kobayashi Y., Furukawa-Hibi Y., Chen C., Horio Y., Isobe K., Ikeda K., and Motoyama N. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int. J. Mol. Med. 16 (2005) 237-243
33. Kops G.J., Medema R.H., Glassford J., Essers M.A., Dijkers P.F., Coffer P.J., Lam E.W., and Burgering B.M. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell. Biol. 22 (2002) 2025-2036
34. Kurokawa H., and Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin. Cancer Res. 9 (2003) 511S-515S
35. Lee B.C., Lee T.H., Avraham S., and Avraham H.K. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol. Cancer Res. 2 (2004) 327-338
36. Li P., Lee H., Guo S., Unterman T.G., Jenster G., and Bai W. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol. Cell. Biol. 23 (2003) 104-118
37. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 19 (2001) 137-148
38. Lynch R.L., Konicek B.W., McNulty A.M., Hanna K.R., Lewis J.E., Neubauer B.L., and Graff J.R. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol. Cancer Res. 3 (2005) 163-169
39. Mazumdar A., and Kumar R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett. 535 (2003) 6-10
40. Modur V., Nagarajan R., Evers B.M., and Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277 (2002) 47928-47937
41. Nakae J., Biggs III W.H., Kitamura T., Cavenee W.K., Wright C.V., Arden K.C., and Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat.Genet. 32 (2002) 245-253
42. Nakamura N., Ramaswamy S., Vazquez F., Signoretti S., Loda M., and Sellers W.R. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. 20 (2000) 8969-8982
43. Nemoto S., Fergusson M.M., and Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306 (2004) 2105-2108
44. Parry P., Wei Y., and Evans G. Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes Chromosomes Cancer 11 (1994) 79-84
45. Ramljak D., Romanczyk L.J., Metheny-Barlow L.J., Thompson N., Knezevic V., Galperin M., Ramesh A., and Dickson R.B. Pentameric procyanidin from Theobroma cacao selectively inhibits growth of human breast cancer cells. Mol. Cancer Ther. 4 (2005) 537-546
46. Reagan-Shaw S., and Ahmad N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res. 66 (2006) 1062-1069
47. Sah J.F., Balasubramanian S., Eckert R.L., and Rorke E.A. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J. Biol. Chem. 279 (2004) 12755-12762
48. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
49. Schroeder F.C., Kau T.R., Silver P.A., and Clardy J. The psammaplysenes, specific inhibitors of FOXO1a nuclear export. J. Nat. Prod. 68 (2005) 574-576
50. Schwab T.S., Madison B.B., Grauman A.R., and Feldman E.L. Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis 10 (2005) 831-840
51. Segrelles C., Moral M., Lara M.F., Ruiz S., Santos M., Leis H., Garcia-Escudero R., Martinez-Cruz A.B., Martinez-Palacio J., Hernandez P., Ballestin C., and Paramio J.M. Molecular determinants of Akt-induced keratinocyte transformation. Oncogene 25 (2006) 1174-1185
52. Seoane J., Le H.V., Shen L., Anderson S.A., and Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117 (2004) 211-223
53. Shapiro D.N., Sublett J.E., Li B., Downing J.R., and Naeve C.W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 53 (1993) 5108-5112
54. So C.W., and Cleary M.L. Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood 101 (2003) 633-639
55. Sourbier C., Lindner V., Lang H., Agouni A., Schordan E., Danilin S., Rothhut S., Jacqmin D., Helwig J.J., and Massfelder T. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res. 66 (2006) 5130-5142
56. Sunters A., Fernandez de M.S., Stahl M., Brosens J.J., Zoumpoulidou G., Saunders C.A., Coffer P.J., Medema R.H., Coombes R.C., and Lam E.W. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278 (2003) 49795-49805
57. van der Heide L.P., and Smidt M.P. Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem. Sci. 30 (2005) 81-86
58. van der Heide L.P., Hoekman M.F., and Smidt M.P. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem. J. 380 (2004) 297-309
59. van der Horst A., Tertoolen L.G., de Vries-Smits L.M., Frye R.A., Medema R.H., and Burgering B.M. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem. 279 (2004) 28873-28879
60. Xia S.J., and Barr F.G. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 23 (2004) 6864-6871
61. Xia W., Bacus S., Hegde P., Husain I., Strum J., Liu L., Paulazzo G., Lyass L., Trusk P., Hill J., Harris J., and Spector N.L. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7795-7800
62. Xuan Z., and Zhang M.Q. From worm to human: bioinformatics approaches to identify FOXO target genes. Mech. Ageing Dev. 126 (2005) 209-215
63. Yamamura Y., Lee W.L., Inoue K., Ida H., and Ito Y. RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J. Biol. Chem. 281 (2006) 5267-5276
64. Yang H., Zhao R., Yang H.Y., and Lee M.H. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene 24 (2005) 1924-1935
65. Yashiroda Y., and Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr. Med. Chem. 10 (2003) 741-748
66. Yau C.Y., Wheeler J.J., Sutton K.L., and Hedley D.W. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res. 65 (2005) 1497-1504
67. You H., and Mak T.W. Crosstalk between p53 and FOXO transcription factors. Cell Cycle 4 (2005) 37-38
68. You H., Jang Y., You-Ten A.I., Okada H., Liepa J., Wakeham A., Zaugg K., and Mak T.W. p53-dependent inhibition of FKHRL1 in response to DNA damage through protein kinase SGK1. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 14057-14062